Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.95 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.65 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361832 | 1.00 | MAOA (1.00) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL4642587 | 1.00 | MAOA (1.00) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL8644839 | 1.00 | MAOA (1.00) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL16260102 | 1.00 | MAOA (1.00) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL8851048 | 1.00 | MAOA (1.00) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL31194846 | 0.98 | MAOA (0.95) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9342131 | 0.98 | MAOA (0.95) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL8021157 | 0.98 | CHRM2 (1.00) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL8021930 | 0.98 | CHRM2 (1.00) | MAOACHRM2SIGMAR1MEN1KMT2A | |
| SCHEMBL3041221 | 0.98 | CHRM2 (1.00) | MAOACHRM2SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5677350-A | Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-dα,ω-diaminoalkanes | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-10-14 | — | — | US | claimed |
| WO-1996040096-A1 | INHIBITION OF CANCER CELL GROWTH, PROLIFERATION AND METASTASIS USING N,N'-DIBENZYL-α,φ-DIAMINOALKANES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-12-19 | — | — | WO | claimed |
| US-20140243340-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBVIE INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8513376-B2 | Polyamides and amidoamines from selectively modified amine amines | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130131085-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120309762-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120237774-A1 | Polyamides and Amidoamines From Selectively Modified Amine Amines | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| US-20080161246-A1 | Improving the pharmacokinetics of drugs such as antiviral agents that are metabolized by CYP enzymes; N-heterocyclic compounds containing carbamate group, where is excluded; 1,3-thiazol-5-ylmethyl 1,1-dibenzylbut-3-enylcarbamate for example | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-20030229037-A1 | Novel cationic amphiphiles | MASSING ULRICH (DE) | 2003-12-11 | — | — | US | disclosed |
| EP-1261620-A2 | CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION | Roche Diagnostics Corporation (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001057064-A2 | CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION | ROCHE DIAGNOSTICS CORPORATION (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-1997048705-A1 | POTASSIUM CHANNEL BLOCKERS | UNIVERSITY COLLEGE LONDON (GB) | 1997-12-24 | — | — | WO | disclosed |
| US-5677350-A | Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-dα,ω-diaminoalkanes | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1996040096-A1 | INHIBITION OF CANCER CELL GROWTH, PROLIFERATION AND METASTASIS USING N,N'-DIBENZYL-α,φ-DIAMINOALKANES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | MAOA 62/4885CHRM2 2148/4885SIGMAR1 495/4885 |
| US-20080161246-A1 | Improving the pharmacokinetics of drugs such as antiviral agents that are metabolized by CYP enzymes; N-heterocyclic compounds containing carbamate group, where is excluded; 1,3-thiazol-5-ylmethyl 1,1-dibenzylbut-3-enylcarbamate for example | CYP3A4, CYP3A5, CYP2B6 | MAOA 376/4885CHRM2 3319/4885SIGMAR1 857/4885 |
| US-20120309762-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | MAOA 62/4885CHRM2 2148/4885SIGMAR1 495/4885 |
| US-20030229037-A1 | Novel cationic amphiphiles | ABHD16A, APMAP, ABCB4 | MAOA 3723/4885CHRM2 4796/4885SIGMAR1 2152/4885 |
| US-20130131085-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | MAOA 62/4885CHRM2 2148/4885SIGMAR1 495/4885 |
| US-20140243340-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | MAOA 62/4885CHRM2 2148/4885SIGMAR1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.